Comparative Pharmacology
Head-to-head clinical analysis: OVCON 35 versus TRI LEGEST 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVCON 35 versus TRI LEGEST 21.
OVCON-35 vs TRI-LEGEST 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH), inhibits ovulation, alters cervical mucus and endometrium.
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
One tablet orally once daily for 21 days, followed by 7 tablet-free days. Each tablet contains norgestimate 0.18 mg/ethinyl estradiol 0.025 mg (days 1-7), norgestimate 0.215 mg/ethinyl estradiol 0.025 mg (days 8-14), norgestimate 0.25 mg/ethinyl estradiol 0.025 mg (days 15-21).
None Documented
None Documented
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norgestimate active metabolite (norelgestromin): 22-36 hours (mean ~28 hours). Steady-state achieved within 5-10 days.
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Renal: approximately 50-60% as metabolites; fecal: approximately 40-50% (ethinyl estradiol and norgestimate metabolites excreted in bile and feces); less than 1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive